SAGE Therapeutics (SAGE) Misses Q1 EPS by 2c

SAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($1.01), $0.02 worse than the analyst estimate of ($0.99). Revenue for the quarter came in at $14.06 million versus the consensus estimate of $14.14 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Robinhood Markets (HOOD) PT Raised to $130 at Cantor Fitzgerald
• Chevron, Microsoft strike 20-year deal to power massive AI data center